BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck Eprova AG and Isofol Medical Enter Exclusive Agreement for Merck Eprova's Modufolin(R) in Oncology


11/11/2009 2:15:07 PM

Schaffhausen/ Switzerland, November 11, 2009 – Today Merck Eprova AG announced that the company has signed an exclusive license agreement with Isofol Medical AB of Sweden to utilize Merck Eprova’s proprietary folate compound Modufolin® in oncology. The use of Modufolin® is expected to enhance effectiveness compared to currently used folate compounds in cancer treatment. Merck Eprova AG will be providing Modufolin®, the active metabolite of LV (Leucovorin), for use in clinical trials and commercial drug products.

After years of intensive research, Merck Eprova AG has succeeded in developing a stable form of the reduced folate Modufolin® ([6R]-5,10-methylenetetrahydrofolate). This breakthrough opens an avenue for testing novel folate-based drug combinations in cancer treatment.

Modufolin® is a biomodulator originally designed to replace LV as the preferred folate to enhance the activity and reduce associated toxicity of 5-FU (5-fluorouracil), a widely used anti-cancer drug. The active form of 5-FU is an inhibitor of the key enzyme TS (thymidylate synthase). Blocking the synthesis of the nucleotide thymidine leads to inhibition of DNA replication and cell death. The effectiveness of 5-FU/LV in combination therapy may be limited due to several metabolic conversions of LV required to generate the pharmacologically active folate compound Modufolin®. In contrast Modufolin® does not need any further metabolic activation. In the tumour tissue this specific form of folate is directly usable by the target enzyme TS, potentially allowing 5-FU to work more effectively.

Isofol Medical AB (www.isofolmedical.com) is a medical development company, based in Sahlgrenska Science Park, Gothenburg, Sweden. The company specializes in the use of Modufolin® in combination with chemotherapeutic agents to increase efficacy and decrease side effects when treating cancer. The founder of Isofol, Prof. Bengt Gustavsson at Sahlgrenska University Hospital in Gothenburg, started research on the effects of reduced folates in combination with chemotherapeutic agents 30 years ago under the world renowned scientist Charles Heidelberger who first synthesized 5-FU. The work led to the discovery of the positive effects of the reduced folate LV in combination with 5-FU in the treatment of cancer. The combination 5-FU/LV has become a standard co-therapy of colorectal cancer, with annual sales of over USD 700 million in US/EU markets. For more than 15 years the research collaboration between Prof. Gustavsson and Merck Eprova AG has been ongoing in the research on effects in combining folates with antifolates in oncology treatment. In pre-clinical and early clinical studies using Modufolin® in combination with chemotherapeutic agents the companies have achieved proof of concept with increased efficacy and decreased side effects vs. LV. Isofol Medical AB has filed for patent protection in all major markets.

Isofol Medical AB will conduct phase I and II studies using a combination of Modufolin® and antifolates starting in autumn 2009 and expected to be finished by the end of 2010.

Merck Eprova AG (www.merckeprova.com), located in Schaffhausen, Switzerland, is a wholly owned subsidiary of Merck KGaA located in Darmstadt, Germany. In the pharmaceutical and nutritional field Merck Eprova AG is recognized as a centre of excellence for reduced folates. Merck Eprova AG is the world's leading supplier of reduced folates such as Leucovorin and Metafolin®. In addition to this focus, Merck Eprova AG specializes in the development and production of cGMP grade, highly purified and characterized drug delivery compounds such as cationic lipids, PEGs, PEG-lipids, and phospholipids.

Merck is a global pharmaceutical and chemical company with total revenues of € 7.6 billion in 2008, a history that began in 1668, and a future shaped by approximately 33,000 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Modufolin® is a registered trademark of Merck KGaA, Darmstadt, Germany Metafolin® is a registered trademark of Merck KGaA, Darmstadt, Germany


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES